Is Profound Medical a buy right now?

Profound Medical Corp. (Profound Medical Corp Stock Quote, Chart, News, Analysts, Financials TSXV:PRN) is sharpening its edge in prostate cancer treatment, as new clinical results from its CAPTAIN trial show its TULSA procedure delivers safer, faster recoveries than traditional surgery, says one analyst.

The CAPTAIN trial compared Profound’s TULSA (Transurethral Ultrasound Ablation) system against robotic prostatectomy for treating prostate cancer. TULSA uses directional ultrasound energy to ablate prostate tissue with precision, offering a minimally invasive alternative to surgery with benefits like zero blood loss, same-day discharge and quicker return to normal activities.

Raymond James analyst Michael Freeman maintained a positive outlook on Profound Medical in an April 29 company brief following new clinical trial results, maintaining his “Strong Buy” rating.

Profound Medical hosted an investor day at the American Urological Association’s 2025 Annual Meeting on April 28, announcing new perioperative safety data from its CAPTAIN clinical trial.

Freeman says the CAPTAIN results strengthen Profound’s case for broader adoption of TULSA.

“With these short-term safety data in hand, supported by long-term prostate cancer efficacy and health-related quality-of-life (HRQoL) data from PROF’s pivotal TACT trial, we think PROF has what it needs to close its first official agreements for coverage by large private insurers (est. late 2025 or early 2026),” Freeman said.

Freeman forecasts that Profound Medical will generate a loss of $26-million in adjusted EBITDA on $19-million in revenue in fiscal 2025.

Freeman added that while Profound appears well-positioned with strong clinical evidence, its commercial success now hinges on its ability to drive installations and broader physician adoption.

“We remain positive on the quality of TULSA’s clinical and real-world evidence, and PROF’s overall opportunity, but acknowledge that we currently lack confirming evidence of TULSA’s widespread uptake (particularly with PROF’s temporary halt of TULSA install count reporting as at 4Q24): PROF’s sales organization has much to prove this/next year,” Freeman said.

-30-